133 studies found for:    "AL amyloidosis"
Show Display Options
Rank Status Study
21 Recruiting A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Conditions: Amyloidosis;   Systemic Light Chain Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone
22 Recruiting Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
23 Completed Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Bortezomib;   Drug: dexamethasone;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation (ASCT);   Drug: Melphalan
24 Recruiting Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
25 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
26 Recruiting Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Conditions: Chronic Kidney Disease;   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Chronic Myelogenous Leukemia (CML);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkin's Lymphoma (NHL);   Hodgkin Disease;   Multiple Myeloma;   Myelodysplastic Syndrome (MDS);   Aplastic Anemia;   AL Amyloidosis;   Diamond Blackfan Anemia;   Myelofibrosis;   Myeloproliferative Disease;   Sickle Cell Anemia;   Autoimmune Diseases;   Thalassemia
Intervention: Procedure: Haploidentical Bone Marrow/Kidney
27 Recruiting A Trial for Systemic Light-chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: BMDex
28 Active, not recruiting Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Conditions: Multiple Myeloma;   Primary Amyloidosis
Interventions: Drug: Melphalan;   Procedure: Stem Cell Infusion;   Behavioral: Questionnaires;   Drug: Granulocyte-colony stimulating factor (G-CSF);   Procedure: Apheresis
29 Completed S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma
Interventions: Biological: recombinant interferon alfa;   Drug: dexamethasone
30 Active, not recruiting CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide
31 Active, not recruiting Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: melphalan
32 Active, not recruiting Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: bortezomib;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
33 Active, not recruiting S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Conditions: Multiple Myeloma;   Plasma Cell Myeloma
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
34 Completed 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Drug: 4'-iodo-4'-deoxydoxorubicin
35 Completed
Has Results
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: lenalidomide
36 Completed High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: melphalan;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation
37 Completed Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide
38 Terminated Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Conditions: Drug/Agent Toxicity by Tissue/Organ;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: amifostine trihydrate;   Drug: melphalan;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation
39 Completed Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Biological: recombinant interferon alfa;   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation
40 Active, not recruiting Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: dexamethasone;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years